Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    High-Throughput Binding Ab Assay Directed Against the S Protein of SARS-CoV-2

    By Global Biodefense StaffApril 17, 2020
    Credit: Richard Eldridge / AFRL
    Share
    Facebook LinkedIn Reddit Email

    Antibody assays are most useful for identifying individuals who have been previously exposed to a particular pathogen. As such, they can be especially valuable, for example, for identification of persons who have had asymptomatic viral infections and for those who have recovered and would no longer be positive in tests for viral nucleic acids. Antibody tests in the context of the current SARS-CoV-2 pandemic are also critical for serosurveillance, for identification of donors for COVID-19 convalescent plasma therapy, and to identify individuals who are potentially immune to reinfection, though this has not yet been established. Antibody assays thus fill an essential gap both during and after the current SARS-CoV-2 pandemic.

    Researchers in this study utilized a Luminex binding assay to assess the presence of antibodies in human sera from COVID-19-infected and -uninfected individuals specific for two recombinant proteins of SARS-CoV-2. The Ab assay described here can be prepared in bulk and used for at least 4 weeks, simplifying the work load and logistics in the laboratory.

    All patient specimens reacted strongly with SARS-CoV-2 antigens although reactivity with the mSpike was generally stronger than with mRBD.

    Further study is needed to ascertain how and whether disease severity affects the level and type of Abs induced. However, it is notable that the level of Abs increased over a period of a few days in each of the two patients from whom researchers had longitudinal specimens.

    Antibody assays of sera can identify individuals who are infected with SARS-CoV-2 and have seroconverted, as well as subjects who have been infected and recovered. The use of the Luminex binding Ab assay has the advantage that it can be run in approximately 2.5 hours, uses very little antigen, and permits a high through-put of samples/day.

    Support for these studies came from the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub (NIH grant U54TR001433); the Personalized Virology Initiative, directed by Dr. Viviana Simon, is supported by institutional funds and philanthropic donations, the Department of Medicine of the Icahn School of Medicine at Mount Sinai Department of Medicine (SZP), the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (VS, FK), the Department of Veterans Affairs (Merit Review Grant I01BX003860 [CEH, SZP, SW] and Research Career Scientist award 1IK6BX004607 [CEH]), the U.S. National Institute of Allergy and Infectious Diseases Investigator Initiated grant (AI139290 [CEH, SZP]) and NIAID grant R01 AI136916 (VS).

    A High Through-put Assay for Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus 2 (SARS-CoV-2). The Journal of Infectious Diseases, 29 August 2020.

    This article was updated to reflect the link to the peer-reviewed paper and remove the pre-print study link from MedRxiv dated April 2020.

    COVID-19 Editor Pick Epidemiology SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleUW Medicine Virology Lab Will Test for Past Infections of New Coronavirus
    Next Article SAFE Act Introduced to Improve Strategic National Stockpile

    Related Stories

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Ontario Supporting $165M Investment to Secure Critical PPE Supply

    December 2, 2023

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.